NL8220049A - Kwaternaire piperidiniumhalogeniden. - Google Patents
Kwaternaire piperidiniumhalogeniden. Download PDFInfo
- Publication number
- NL8220049A NL8220049A NL8220049A NL8220049A NL8220049A NL 8220049 A NL8220049 A NL 8220049A NL 8220049 A NL8220049 A NL 8220049A NL 8220049 A NL8220049 A NL 8220049A NL 8220049 A NL8220049 A NL 8220049A
- Authority
- NL
- Netherlands
- Prior art keywords
- compound
- formula
- piperidinium
- benzyl
- encainide
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 150000004820 halides Chemical class 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- -1 methoxybenzoyl Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000012467 final product Substances 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- PJWPNDMDCLXCOM-UHFFFAOYSA-N encainide Chemical compound C1=CC(OC)=CC=C1C(=O)NC1=CC=CC=C1CCC1N(C)CCCC1 PJWPNDMDCLXCOM-UHFFFAOYSA-N 0.000 description 11
- 229960001142 encainide Drugs 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000003288 anthiarrhythmic effect Effects 0.000 description 3
- 239000003416 antiarrhythmic agent Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22924481 | 1981-01-28 | ||
| US06/229,244 US4321386A (en) | 1981-01-28 | 1981-01-28 | Quaternary piperidinium halides |
| US8200108 | 1982-01-27 | ||
| PCT/US1982/000108 WO1982002551A1 (en) | 1981-01-28 | 1982-01-27 | Quaternary piperidinium halides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8220049A true NL8220049A (nl) | 1982-11-01 |
Family
ID=22860396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8220049A NL8220049A (nl) | 1981-01-28 | 1982-01-28 | Kwaternaire piperidiniumhalogeniden. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4321386A (enExample) |
| JP (1) | JPH0348904B2 (enExample) |
| AR (1) | AR230266A1 (enExample) |
| AT (1) | AT378183B (enExample) |
| AU (1) | AU551523B2 (enExample) |
| BE (1) | BE891938A (enExample) |
| CA (1) | CA1184917A (enExample) |
| CH (1) | CH651021A5 (enExample) |
| DE (1) | DE3223499T1 (enExample) |
| DK (1) | DK156649C (enExample) |
| FI (1) | FI65239C (enExample) |
| GB (1) | GB2100736B (enExample) |
| GR (1) | GR74720B (enExample) |
| IE (1) | IE52420B1 (enExample) |
| IT (1) | IT1147809B (enExample) |
| NL (1) | NL8220049A (enExample) |
| SE (1) | SE435057B (enExample) |
| WO (1) | WO1982002551A1 (enExample) |
| YU (1) | YU43063B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1007624A2 (pt) * | 2009-04-09 | 2016-07-26 | Cognition Therapeutics Inc | composto, método para preparar uma composição, composto ou sal farmaceuticamente aceitável deste e uso de um composto ou um sal farmaceuticamente aceitável deste |
| SG10201506978UA (en) | 2009-07-31 | 2015-10-29 | Cognition Therapeutics Inc | Inhibitors Of Cognitive Decline |
| WO2012106426A1 (en) | 2011-02-02 | 2012-08-09 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
| EP3099296B1 (en) | 2014-01-31 | 2019-01-30 | Cognition Therapeutics, Inc. | Isoindoline derivative, compositions and methods for treating neurodegenerative disease |
| US11214540B2 (en) | 2017-05-15 | 2022-01-04 | Cognition Therapeutics, Inc. | Compositions for treating neurodegenerative diseases |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3037910A (en) * | 1958-04-18 | 1962-06-05 | Burroughs Wellcome Co | Process for treatment of hypertension |
| US3931195A (en) * | 1971-03-03 | 1976-01-06 | Mead Johnson & Company | Substituted piperidines |
| US3917679A (en) * | 1974-04-12 | 1975-11-04 | Lilly Co Eli | Quaternary ammonium salts of N-dialkylaminoalkyl-N-(2-indanyl)anilines |
-
1981
- 1981-01-28 US US06/229,244 patent/US4321386A/en not_active Expired - Lifetime
-
1982
- 1982-01-27 CH CH5828/82A patent/CH651021A5/de not_active IP Right Cessation
- 1982-01-27 WO PCT/US1982/000108 patent/WO1982002551A1/en not_active Ceased
- 1982-01-27 JP JP57500784A patent/JPH0348904B2/ja not_active Expired - Lifetime
- 1982-01-27 AT AT0900782A patent/AT378183B/de active
- 1982-01-27 DE DE823223499T patent/DE3223499T1/de active Granted
- 1982-01-27 AU AU81485/82A patent/AU551523B2/en not_active Ceased
- 1982-01-27 GB GB08220076A patent/GB2100736B/en not_active Expired
- 1982-01-28 BE BE0/207171A patent/BE891938A/fr not_active IP Right Cessation
- 1982-01-28 YU YU197/82A patent/YU43063B/xx unknown
- 1982-01-28 IE IE191/82A patent/IE52420B1/en unknown
- 1982-01-28 NL NL8220049A patent/NL8220049A/nl unknown
- 1982-01-28 CA CA000395068A patent/CA1184917A/en not_active Expired
- 1982-01-28 AR AR288281A patent/AR230266A1/es active
- 1982-01-28 GR GR67146A patent/GR74720B/el unknown
- 1982-01-28 IT IT47667/82A patent/IT1147809B/it active
- 1982-07-08 FI FI822443A patent/FI65239C/fi not_active IP Right Cessation
- 1982-09-27 DK DK429382A patent/DK156649C/da not_active IP Right Cessation
- 1982-09-28 SE SE8205535A patent/SE435057B/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AR230266A1 (es) | 1984-03-01 |
| AT378183B (de) | 1985-06-25 |
| IT1147809B (it) | 1986-11-26 |
| SE435057B (sv) | 1984-09-03 |
| US4321386A (en) | 1982-03-23 |
| AU8148582A (en) | 1982-08-16 |
| IT8247667A0 (it) | 1982-01-28 |
| AU551523B2 (en) | 1986-05-01 |
| GB2100736A (en) | 1983-01-06 |
| DK156649C (da) | 1990-02-05 |
| GR74720B (enExample) | 1984-07-10 |
| JPS57502216A (enExample) | 1982-12-16 |
| ATA900782A (de) | 1984-11-15 |
| DE3223499C2 (enExample) | 1989-11-23 |
| SE8205535L (sv) | 1982-09-28 |
| FI822443A0 (fi) | 1982-07-08 |
| GB2100736B (en) | 1985-01-30 |
| FI65239B (fi) | 1983-12-30 |
| YU19782A (en) | 1985-04-30 |
| DK156649B (da) | 1989-09-18 |
| YU43063B (en) | 1989-02-28 |
| FI65239C (fi) | 1984-04-10 |
| IE52420B1 (en) | 1987-10-28 |
| FI822443L (fi) | 1982-07-08 |
| BE891938A (fr) | 1982-07-28 |
| CA1184917A (en) | 1985-04-02 |
| IE820191L (en) | 1982-07-28 |
| DE3223499T1 (de) | 1983-01-13 |
| SE8205535D0 (sv) | 1982-09-28 |
| DK429382A (da) | 1982-09-27 |
| CH651021A5 (de) | 1985-08-30 |
| JPH0348904B2 (enExample) | 1991-07-25 |
| WO1982002551A1 (en) | 1982-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lan et al. | Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand | |
| Byrnes et al. | New antiarrhythmic agents. 1. Primary. alpha.-amino anilides | |
| Portoghese et al. | Stereochemical studies on medicinal agents. 13. Correlation of the solid-state conformations of 1, 3, 5-trimethyl-and 1, 3-dimethyl-4-phenyl-4-propionoxypiperidine enantiomers with their absolute stereoselectivity at analgetic receptors | |
| JPS62198666A (ja) | １−ベンジル−２−／ｎ−置換／−カルバモイル−テトラヒドロイソキノリン及びその製造方法 | |
| NL8220049A (nl) | Kwaternaire piperidiniumhalogeniden. | |
| Gul et al. | Syntheses and stability studies of some Mannich bases of acetophenones and evaluation of their cytotoxicity against Jurkat cells | |
| FI75337B (fi) | Foerfarande foer framstaellning av 9-(3-isopropylaminopropyl)-9-karbamoylfluoren, samt ny mellanprodukt. | |
| DE2919800A1 (de) | 4-amino-2-piperidinochinazolin-derivate, verfahren zu ihrer herstellung und solche derivate enthaltende arzneimittel | |
| Tenthorey et al. | New antiarrhythmic agents. 6. Quantitative structure-activity relationships of aminoxylidides | |
| Tan et al. | Rapid synthesis of F‐18 and H‐2 dual‐labeled altanserin, a metabolically resistant PET ligand for 5‐HT2a receptors | |
| SK143096A3 (en) | Novel hydroximic acid derivatives, pharmaceutical compositions containing them and process for preparing same | |
| DE3900028A1 (de) | Gegebenenfalls am phenylrest halogen- und/oder alkyl- und/oder alkoxy- oder methylendioxysubstituierte, 5,5-di-(methyl)-3-(phenylvinyl)-1-(substituiert amino-alkoxy-imino)-cyclohex-2-enderivate, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel | |
| US4056540A (en) | 4-Phenyl-1,3-benzodioxans | |
| DE2303427C3 (de) | Dibenzo-(a,d)-cycloheptadiene und -triene, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| US2914533A (en) | Tertiary-aminoalkyl n-(pyridyl)carbamates and their preparation | |
| KR101543667B1 (ko) | 광학활성 2-아미노 트리아졸 유도체 및 이의 제조방법 | |
| Kametani et al. | Synthesis of heterocyclic compounds. CCLXXXXV. Syntheses of benzomorphan and related compounds. II. The debenzylation of quaternary ammonium salts with thiophenol | |
| Tominaga et al. | Iodinated derivatives of histamine and N-acetylhistamine | |
| FR2521137A1 (fr) | Halogenures de piperidinium quaternaire | |
| FI59089C (fi) | Foerfarande foer framstaellning av 5-endobensoyloxi-n-(amino-(laegre)alkyl)bicyklo(2,2,1)heptan-2,3-di-endokarboxylsyraimider motverkande oregelbunden hjaertverksamhet | |
| Nasielski‐Hinkens et al. | Nucleophilic substitutions on 2‐Chloro‐3‐Nitroquinoxaline | |
| Debellis et al. | PRONOUNCED CONFORMATIONAL PREFERENCE OF THE 3′‐α‐CUMYL SUBSTITUENT IN 2‐(2′‐METHOXY‐3′‐α‐CUMYLPHENYL) BENZOTRIAZOLE | |
| Dolfini et al. | The reaction of. alpha.-nitro-. alpha. haloalkanes with imines. Synthesis of 3-nitropyrrolidines and 3-nitropiperidines | |
| Mathison et al. | Synthesis, stereochemistry, and antiarrhythmic activity of some 8-substituted decahydroisoquinolines | |
| DE2760038C2 (enExample) |